Jankey DM 10mg/1000mg/100mg Tablet

Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby reducing plasma glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, leading to increased insulin release and decreased glucagon secretion in a glucose-dependent manner.

The combined mechanism of action addresses multiple pathophysiological defects in type 2 diabetes, offering improved glycemic control with a reduced risk of hypoglycemia compared to traditional therapies. Jankey DM is administered orally, typically once or twice daily with meals to minimize gastrointestinal side effects. It is contraindicated in patients with severe renal impairment, diabetic ketoacidosis, or hypersensitivity to any component.

Regular monitoring of renal function and glycemic parameters is recommended during therapy to ensure safety and efficacy.